Diabetic neuropathy (DN), a common and debilitating complication of type
2 diabetes, is characterized by chronic pain that significantly impacts
patients' quality of life. Available treatments, such as pregabalin or
duloxetine, provide limited efficacy and are often associated with significant
side effects. In light of these challenges, identifying complementary solutions
is critical to better managing symptoms. A recent study proposes an innovative
alternative: a nutritional supplement cocktail aimed at reducing neuropathic
pain and restoring nerve function.
A promising cocktail for neuropathic pain relief?
The study included 73 adult patients with type 2 diabetes and moderate
DN symptoms. Participants were divided into two groups:
- Active group:
supplementation with a cocktail containing palmitoylethanolamide (PEA),
superoxide dismutase, alpha-lipoic acid, vitamins (B1, B6, B12, E, and
nicotinamide), magnesium, and zinc.
- Placebo group:
supplementation without active ingredients.
The effectiveness of this novel treatment was evaluated before and after
six months of supplementation, focusing on the following outcomes: pain
intensity, nerve function (sural conduction velocity and action potential
amplitude), vibratory perception threshold, sudomotor function, disease-related
quality of life, and neurological assessments (MNSIQ and MNSIE).
The results revealed a significant reduction in pain in the active
group, along with notable improvements in nerve function: increased vitamin B12
levels, better MNSIQ scores, enhanced vibratory perception thresholds, and
improved electrodermal conductance in the feet.
In contrast, the placebo group showed no significant progress, and a
deterioration in MNSIQ scores was observed.
An innovative approach to neuropathic pain
This study demonstrates that a nutritional supplement cocktail,
including PEA and vitamin B12, can effectively reduce neuropathic pain and
improve certain functional markers in patients with diabetic neuropathy.
While these results are promising, they require validation through larger-scale
studies to establish this approach as an effective complement to conventional
treatments. The variability in symptom improvement suggests that baseline pain
severity may influence treatment outcomes.
